Key Highlights
- Revenue was USD 7.30 million, up from about USD 7 million in the second quarter, and no estimates were available.
- Adjusted EBITDA was about USD 400,000, consistent with the second quarter, and Operating Cash Flow was about USD 600,000.
- Cash rose about USD 0.5 million in the quarter to above USD 3.5 million, against about USD 2.3 million.
- The filing states substantial doubt about continuing as a going concern, with an accumulated Deficit of USD 104.5 million.
Precipio, Inc. (NASDAQ:PRPO), a diagnostics company, reported third quarter 2026 Revenue of USD 7.30 million, up from about USD 7 million in the second quarter. No revenue or Earnings estimates were available for the quarter. Management said adjusted EBITDA was about USD 400,000, consistent with the second quarter, and operating cash flow was about USD 600,000 against about USD 700,000.
The filing states that patient diagnostic service revenue increased USD 0.3 million from the same period in 2025, and product revenue increased USD 0.3 million primarily on revenue from new product related projects. Gross Profit increased USD 0.4 million. Management said its 2025 results were relatively flat in revenue and that it viewed that period as a learning experience that informs how its sales team targets the market.
Loss, Cash and Going Concern
The filing shows a loss per share of nil for the third quarter against USD 0.05 a year earlier, and USD 0.93 for the nine months against USD 0.57, on about 1.8 million weighted-average shares. Total cash increased about USD 0.5 million during the quarter to above USD 3.5 million, against about USD 2.3 million a year earlier.
The filing states an accumulated deficit of USD 104.5 million and Working Capital of USD 3.1 million at September 30, 2026. It also states that substantial doubt remains about the company's ability to continue as a Going Concern over the next twelve months from the date of issuance, and that there is no assurance it can achieve the initiatives it describes.
Run Rate Targets for 2027
Management said its 2025 focus was reaching positive cash flow and that, in 2026, as it generated cash, it refined the commercial approach it believes can scale its products business. For the product division, it is targeting an annualized revenue run rate above USD 10 million by the end of 2027 against an annualized run rate of about USD 4 million based on third quarter results.
It also targets an annualized run rate of about USD 30 million for its services Business by the end of 2027, for a combined run rate above USD 40 million. Management said these are targets for the annualized run rate it aims to exit 2027 with rather than a forecast of revenue recognized during the year.
Legal Disclosure and Items to Follow
The filing's Legal Proceedings section describes the laws and regulations that apply to the healthcare industry, including licensure, accreditation and government healthcare program participation, and is reported as stated. It is flagged for human legal review. The items to follow are product revenue growth, services volume, gross profit, cash and the going concern note.






Please wait processing your request...